2022 AACR 年会将于美东时间4月8日至13日在路易斯安那州新奥尔良举行。作为癌症研究界关注的焦点，来自世界各地的科学家、临床医生、其他医疗保健专业人员、幸存者和倡导者齐聚一堂，分享癌症科学和医学的最新进展。
日前，此次会议上消化领域的壁报已新鲜出炉，【肿瘤资讯】特将胃肠道肿瘤、肝癌、胰腺癌三项重头大戏的学术研究信息汇总如下，快来在留言区Pick你最期待的研究吧！
胃肠道肿瘤
免疫联合靶向治疗
1.Trastuzumab deruxtecan(T-DXd)联合adavosertib 在HER2表达Cyclin E扩增的胃食管癌中的抗肿瘤疗效
Antitumor efficacy of trastuzumab deruxtecan in combination with adavosertib in HER2-expressing Cyclin E amplified gastroesophageal cancers
第一作者：Timothy P. DiPeri
摘要编号：327/2
2.抑制HGF成熟克服结直肠癌对西妥昔单抗的耐药性
Inhibition of HGF maturation overcomes cetuximab resistance in colorectal cancer
第一作者：Ramona Graves-Deal
摘要编号：1525/5
3.西妥昔单抗和达沙替尼治疗BRAF突变结肠癌细胞的原位小鼠模型研究
The orthotopic mouse study of cetuximab and dasatinib treatment on BRAF mutated colon cancer cells
第一作者：Yu-Cheng Weng
摘要编号：1626/18
4.回顾性研究：晚期胃/胃食管结合部腺癌患者对曲妥珠单抗长期治疗的反应
Long-term response to Trastuzumab in patients with advanced gastric or gastroesophageal adenocarcinoma - A retrospective study
第一作者：Isabel Porth
摘要编号：4018/12
5.曲妥珠单抗联合抗PD-1药物治疗HER2阳性胃癌后血浆ctDNA特征的临床意义
Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & anti-PD-1 agents
第一作者：Xiaoyi Chong
摘要编号：5129
6.MET抑制可克服KRAS、NRAS和BRAF野生型结直肠癌中肝细胞生长因子诱导的西妥昔单抗耐药性
Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancer
第一作者：Sang-A Kim
摘要编号：5138
7.揭秘IV期HER2阳性胃癌患者曲妥珠单抗耐药的分子机制
Dissecting the molecular mechanism of trastuzumab resistance in stage IV HER2-positive gastric cancer patients
第一作者：Qi Xu
摘要编号：5336
8.TP53热点突变使APC突变的结直肠癌细胞在体外对西妥昔单抗敏感
Hotspot mutations of TP53 sensitize APC-mutated colorectal cancer cells to cetuximab in vitro
第一作者：Mingli Yang
摘要编号：5366
靶向联合化疗治疗
1.通过无偏倚高通量筛选确定MEK抑制剂曲美替尼联合长春新碱治疗RAS突变结直肠癌细胞的疗效
Determining efficacy of combining the MEK inhibitor trametinib with vincristine identified by unbiased high throughput screening in RAS-mutated colorectal cancer cells
第一作者：Susmita Ghosh
摘要编号：1056/11
2.结直肠癌患者中基于p53状态和FOLFOX、5-FU、奥沙利铂或伊立替康个体化治疗方案的预后及预测药物诱导的基因标记
Prognostic and predictive drug-induced gene signatures for colorectal cancer patients personalized based on p53 status and treatment with FOLFOX, 5-FU, oxaliplatin, or irinotecan
第一作者：Lindsey Carlsen
摘要编号：1231/3
3.病例报告：信迪利单抗联合贝伐珠单抗治疗微卫星稳定的强化预治疗难治性结肠癌患者的长期疗效
Case report: long-term response to combination of Sintilimab, Bevacizumab and chemotherapy in a heavily pretreated refractory colon cancer patient with microsatellite stability
第一作者：Zhi Cui
摘要编号：5190
4.UGT1A1基因多态性与伊立替康单药二线治疗晚期胃癌安全性及疗效的相关性
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the second-line treatment for advanced gastric cancer
第一作者：Huifang Lv
摘要编号：5250
5.PD-1抗体联合卡瑞利珠单抗治疗策略克服HER2阳性转移性胆囊癌患者对曲妥珠单抗联合化疗的耐药性
Addition of PD-1 antibody camrelizumab overcame resistance to trastuzumab plus chemotherapy in a HER2-positive, metastatic gallbladder cancer patient
第一作者：Dong Yan
摘要编号：5517
6.针对胃癌异质性化疗和靶向治疗的临床前研究
Preclinical studies of chemotherapies and targeted therapies to address gastric cancer disparities
第一作者：Hongyong Zhang
摘要编号：3108/15
免疫联合化疗
1.微卫星稳定(MSS)转移性结直肠癌(mCRC)短程奥沙利铂化疗后纳武利尤单抗治疗反应的早期放射学征象
Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
第一作者：Sebastian Meltzer
摘要编号：1279/1
2.可手术的食管癌患者中放化疗和免疫治疗联合反应改善呈现不同的微生物组特征并富集于多种拟杆菌属
Patients with operable esophageal cancer and improved responses to combined chemoradiotherapy and immunotherapy display distinct microbiome profiles enriched in multiple Bacteroides species
第一作者：Fyza Y. Shaikh
摘要编号：1973/5
3.PD-1抑制剂联合化疗一线治疗胃/胃食管结合部肿瘤疗效的预测性生物标志物
Predictive biomarkers for the efficacy of PD-1 inhibitors plus chemotherapy for gastric/gastroesophageal junction cancer in first-line setting
第一作者：Yu-Ting Sun
摘要编号：5092
4.CD56 dim+免疫浸润及重编程TMEs与局部晚期胃/胃食管结合部腺癌接受新辅助抗PD-1免疫治疗联合同步放化疗的反应相关
CD56 dim+ immune infiltration and reprogrammed TMEs associated with response to neoadjuvant anti-PD-1 immunotherapy plus concurrent chemoradiotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma
第一作者：Jia Wei
摘要编号：6176
肝癌
靶向治疗
1.CDK 4/6抑制剂哌柏西利与雷帕霉素联合使用协同抑制肝癌细胞的生长
Combination of CDK 4/6 inhibitor Palbociclib with Rapamycin synergistically inhibits the growth of hepatocellular carcinoma cells
第一作者：Ankur Tiwari
摘要编号：1046/1
2.Romidepsin治疗可诱导p53介导肝母细胞瘤发生细胞凋亡
Romidepsin therapy results in p53 mediated apoptosis in hepatoblastoma
第一作者：Andres F. Espinoza
摘要编号：1825/23
3.真实世界研究：阿帕替尼治疗不可切除肝细胞癌的疗效和安全性
Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study
第一作者：Jun Liu
摘要编号：5249
4.RNase7指导针对肝细胞癌的抗ROS1靶向治疗
RNase7-guided anti-ROS1 targeted therapy for hepatocellular carcinoma
第一作者：Chunxiao Liu
摘要编号：5286
5.miR-15a和miR-20b通过抑制CDC37L1及PPIA下调增强索拉非尼对肝细胞癌的敏感性
miR-15a & miR-20b enhance sorafenib sensitivity of hepatocellular carcinoma through repressing CDC37L1 and consequent PPIA downregulation
第一作者：Li Li
摘要编号：5347
免疫治疗
1.临床前研究：肝细胞癌在小鼠模型中的全面和功能性免疫治疗研究
Mouse models of hepatocellular carcinoma: A comprehensive and functional preclinical platform for immunotherapy research
第一作者：Olivier Duchamp
摘要编号：1654/16
2.致癌融合蛋白DNAJB1-PRKACA可通过基于肽的免疫治疗在纤维板层肝细胞癌中主动靶向出击
The oncogenic fusion protein DNAJB1-PRKACA can be actively targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
第一作者：Jens Bauer
摘要编号：2008/12
3.免疫阴性基因对肝癌免疫治疗联合抗血管治疗的影响
Effects of immune negative genes on immunotherapy combined anti-vascular for liver cancer
第一作者：Xinhua Zhu
摘要编号：5086
4.预测晚期不可切除肝癌免疫治疗抗肿瘤反应的循环生物标志物
Circulating biomarkers to predict antitumor response to immunotherapy in advanced unresectable hepatoma
第一作者：Lynn G. Feun
摘要编号：2771/5
5.调节性T细胞抑制小鼠肝肿瘤免疫治疗的疗效
Regulatory T cells restrain efficacy of immunotherapy in murine liver tumors
第一作者：Benjamin L. Green
摘要编号：2582/21
联合治疗
1. 12-趋化因子基因特征用于鉴别接受新辅助纳武单抗和卡博替尼治疗的肝细胞癌患者的主要病理反应
12-chemokine gene signature identifies major pathologic response in patients with hepatocellular carcinoma treated with neoadjuvant nivolumab and cabozantinib
第一作者：Daniel H. Shu
摘要编号：1323/12
2.利用晚期肝细胞癌空间转录组学区分卡博替尼和纳武利尤单抗新辅助治疗后应答者和无应答者的细胞间相互作用
Spatial transcriptomics of advanced hepatocellular carcinomas distinguishes intercellular interactions in responders and non-responders to cabozantinib and nivolumab neoadjuvant therapy
第一作者：Luciane T. Kagohara
摘要编号：3820/20
胰腺癌
1.β-羟基-β-甲基丁酸促进胰腺癌小鼠模型的免疫治疗反应和促炎巨噬细胞极化
β-Hydroxy-β-methylbutyrate promotes immunotherapy response and pro-inflammatory macrophage polarization in a mouse model of pancreatic cancer
第一作者：Michael F. Coleman
摘要编号：1995/7
2.MEK和STAT3联合抑制重编程肿瘤微环境可克服胰腺癌免疫治疗耐药性
Combined MEK and STAT3 inhibition reprograms the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer
第一作者：Vanessa Tonin Garrido
摘要编号：4187/23
3.中国胰腺癌患者免疫治疗相关生物标志物的综合分析和潜在临床应用
Comprehensive analysis and potential clinical applications of immunotherapy-related biomarkers in Chinese patients with pancreatic adenocarcinoma
第一作者：Yu Wang
摘要编号：5753
4.功能获得性p53 R172H突变驱动中性粒细胞在胰腺肿瘤微环境中聚集促进对免疫治疗的抵抗
Gain-of-function p53R172H mutation drives accumulation of neutrophils in the pancreatic tumor microenvironment promoting resistance to immunotherapy
第一作者：Despina Siolas
摘要编号：6142
5.葡萄糖对胰腺癌模型中巨噬细胞代谢和对免疫治疗的重要反应
Glucose is important for macrophage metabolism and response to immunotherapy in a pancreatic cancer model
第一作者：Jonathan J. Hue
摘要编号：3133/11
1.亚胺培酮ONC212联合曲美替尼治疗通过免疫介导机制在胰腺导管腺癌细胞系中表现出抗肿瘤作用
Imipridone ONC212 and trametinib combination therapy demonstrates anti-neoplastic effects through immune-mediated mechanisms in pancreatic ductal adenocarcinoma cell lines
第一作者：Alexander G. Raufi
摘要编号：319/11
2.利用间皮素结合肽鉴定胰腺癌靶向治疗
Identification of mesothelin binding peptide for targeted therapy against pancreatic cancer
第一作者：Min-Sung Park
摘要编号：1743/12
3.Selumetinib通过HSF1途径诱导自噬在K-Ras突变胰腺癌中表现出新效果
Novel effect of Selumetinib-mediated autophagy via HSF1 in K-Ras mutant pancreatic cancer
第一作者：Shruti Ghai
摘要编号：3004/11
1.吉西他滨/白蛋白结合型紫杉醇难治性转移性胰腺癌患者的肿瘤细胞和巨噬细胞上可见PD-L1表达水平升高
Increased PD-L1 expression levels were observed on both tumor cells and macrophages by tocilizumab plus gemcitabine/nab-paclitaxel treatment in gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer patients
第一作者：Kyoko Yamaguchi
摘要编号：6145
2.S-1联合信迪利单抗和安罗替尼二线治疗胰腺癌肝转移患者的有效性和安全性：单臂、II期临床试验
Efficacy and safety of second-line therapy by S-1 combined with Sintilimab and Anlotinib in pancreatic cancer patients with liver metastasis: A single-arm, phase II clinical trial
第一作者：Juan Du
摘要编号：5192
https://www.aacr.org/meeting/aacr-annual-meeting-2022/
排版编辑：肿瘤资讯-Bree
苏公网安备32059002004080号
